Gene · 2202
Papers1,739
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 1,739
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma. | Med Lav | 2022 | 36475505 | PubTator, text mining | PubMed |
| VEGFA rs3025039 and biliary atresia susceptibility in Chinese population: a systematic review and meta-analysis. | World J Pediatr Surg | 2022 | 36474631 | PubTator, text mining | PubMed |
| Novel expression cassettes for increasing apolipoprotein AI transgene expression in vascular endothelial cells. | Sci Rep | 2022 | 36473901 | PubTator, text mining | PubMed |
| M7G-related LncRNAs: A comprehensive analysis of the prognosis and immunity in glioma. | Front Genet | 2022 | 36468039 | PubTator, text mining | PubMed |
| Genetic epidemiology of inherited retinal diseases in a large patient cohort followed at a single center in Italy. | Sci Rep | 2022 | 36460718 | PubTator, text mining | PubMed |
| Thrombospondin 1 missense alleles induce extracellular matrix protein aggregation and TM dysfunction in congenital glaucoma. | J Clin Invest | 2022 | 36453543 | PubTator, text mining | PubMed |
| Identification of Factors Driving Doxorubicin-Resistant Ewing Tumor Cells to Survival. | Cancers (Basel) | 2022 | 36428591 | PubTator, text mining | PubMed |
| A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. | JTO Clin Res Rep | 2022 | 36426287 | PubTator, text mining | PubMed |
| Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient. | Genes (Basel) | 2022 | 36421778 | PubTator, text mining | PubMed |
| Potential blood biomarkers for chronic traumatic encephalopathy: The multi-omics landscape of an observational cohort. | Front Aging Neurosci | 2022 | 36420308 | PubTator, text mining | PubMed |
| Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction. | Front Oncol | 2022 | 36408130 | PubTator, text mining | PubMed |
| Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19. | Front Immunol | 2022 | 36405747 | PubTator, text mining | PubMed |
| GediNET for discovering gene associations across diseases using knowledge based machine learning approach. | Sci Rep | 2022 | 36402891 | PubTator, text mining | PubMed |
| Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population. | Nat Commun | 2022 | 36402758 | PubTator, text mining | PubMed |
| EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways. | J Bone Oncol | 2022 | 36388640 | PubTator, text mining | PubMed |
| Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology. | Front Endocrinol (Lausanne) | 2022 | 36387901 | PubTator, text mining | PubMed |
| Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines. | Sci Rep | 2022 | 36371458 | PubTator, text mining | PubMed |
| Identification of the hub susceptibility genes and related common transcription factors in the skeletal muscle of Type 2 Diabetes Mellitus. | BMC Endocr Disord | 2022 | 36368953 | PubTator, text mining | PubMed |
| Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential. | Int J Mol Sci | 2022 | 36362067 | PubTator, text mining | PubMed |
| Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma. | Biomedicines | 2022 | 36359323 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2202/papers?page=18